US Stock MarketDetailed Quotes
THTX Theratechnologies
- 1.8000
- +0.0800+4.65%
Close Jan 15 16:00 ET
82.76MMarket Cap-45.00P/E (TTM)
1.8299High1.7500Low158.51KVolume1.7800Open1.7200Pre Close281.96KTurnover0.46%Turnover RatioLossP/E (Static)45.98MShares2.180052wk High-4.21P/B61.64MFloat Cap1.080052wk Low--Dividend TTM34.24MShs Float17.8400Historical High--Div YieldTTM4.65%Amplitude0.8800Historical Low1.7780Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Theratechnologies Stock Forum
Theratechnologies Provides Update on EGRIFTA SV® Supply
28 minutes ago, 2:05 PM PST
Via GlobeNewswire
THTX
Share
MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that a shortage of EGRIFTA SV® (tesamorelin for injection) will occur at the patient level in mid-January...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
Tuesday, 10th December at 3:15 pm
MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United States Food and Drug Administration (FDA) has assigned a Prescriptio...
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients
Preliminary evidence of dose response includes significant tumor shrinkage and one patient with complete resolution of a liver lesion
MONTREAL, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologie...
MT Newswires· 4 mins ago
Theratechnologies Announces Resumed Production of EGRIFTA SV®
Tuesday, 3rd December at 4:30 pm
MONTREAL, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the production of EGRIFTA SV® has resumed following a voluntary shutdown of the Company's contract manufacturer's fa...
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec
Monday, 2nd December at 7:30 am
• New financing replaces existing credit facility to optimize Company's capital structure
• Favorable interest rates and amortization schedules to free up approximately $19 million in cash in 2025 to support business development strategy
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) presented data at IDWeek 2024 highlighting the impact of excess visceral abdominal fat (EVAF) on cardiovascular disease (CVD) risk in people with HIV (PWH). Two studies were presented:
1. The VAMOS study showed that EVAF is prevalent (58%) in PWH on modern anti-r...
Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
• Q3 revenue of $22.6 million represents +8% growth year-over-year
• Positive net income of $3.1 million or 6 cents per share, and Adjusted EBITDA1 of $7.2 million
• Fiscal 2024 guidance revised to between $83 and $85 million in revenue and Adjusted EBITDA guidance increased to a range of $17 to $19 million
NEWS
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Theratechnologies announced promising Phase 1 data for its investigational drug, sudocetaxel zendusortide, at the 2024 ASCO annual meeting.
The drug showed long-term disease stabilization in patients with solid tumors, lasting up to 45 weeks even after treatment ceased.
The study highlighted a uni...
No comment yet